98 related articles for article (PubMed ID: 8135468)
1. A phase II multi-institutional study of estra-1,3,5(10)-triene-3,17 beta-diol, 3-benzoate, 17[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1- oxobutoxy]acetate] (KM2210), a novel antitumor agent, for advanced and recurrent breast carcinoma.
Kubota T; Abe O; Izuo M; Watanabe H; Enomoto K; Ohsawa N; Kuno K
Anticancer Res; 1993; 13(6B):2361-5. PubMed ID: 8135468
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of estra-1,3,5(10)-triene-3, 17 beta-diol, 3-benzoate, 17[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy] acetate] (KM2210) on MCF-7 human breast tumours transplanted into nude mice.
Kubota T; Ishibiki K; Abe O; Kosano H; Ohsawa N; Hoffman RM
Anticancer Res; 1993; 13(4):935-40. PubMed ID: 8352562
[TBL] [Abstract][Full Text] [Related]
3. [Enhancement of antitumor activity of mitomycin C against human breast carcinoma xenografts by pretreatment with KM 2210].
Yamamoto T; Kubota T; Oka S; Josui K; Fujita S; Arisawa Y; Suto A; Inoue S; Kuzuoka M; Ishibiki K
Gan To Kagaku Ryoho; 1990 Jan; 17(1):109-14. PubMed ID: 2105084
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and pharmacokinetics of estra-1,3,5 (10)-triene-3,17 beta-diol, 3-benzoate, 17-((4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy) acetate) (Bestrabucil) in human tumor xenografts serially transplanted into nude mice.
Kubota T; Kawamura E; Suzuki T; Yamada T; Toyoda H; Miyagawa T; Kurokawa T
Jpn J Clin Oncol; 1986 Dec; 16(4):357-64. PubMed ID: 3795532
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
Ueda T; Sakai K; Morimoto K; Nakatani S
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3285-9. PubMed ID: 3688892
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of recurrent breast carcinoma achieving CR (complete response) with KM2210].
Kubota T; Yamada Y; Kawamura E; Toyoda H; Miyagawa T; Kurokawa T
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2556-9. PubMed ID: 3619463
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
8. Mode of action of estra-1,3,5(10)-triene-3,17 beta-diol 3-benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acet ate) on human breast carcinoma xenografts in nude mice.
Kubota T; Koh J; Yamada Y; Oka S; Enomoto K; Ishibiki K; Abe O; Masui O; Asano K
Jpn J Cancer Res; 1988 Nov; 79(11):1224-9. PubMed ID: 3147278
[TBL] [Abstract][Full Text] [Related]
9. Growth-inhibitory action of an estrogen-chlorambucil conjugate (KM2210) in human breast cancer cell line MCF-7: its relation to reduction of estrogen receptor and transforming growth factor-alpha secretion.
Kosano H; Kubota T; Ohsawa N; Yamamori S; Abe O; Inagaki H; Nagata N
Cancer Res; 1992 Mar; 52(5):1187-91. PubMed ID: 1737378
[TBL] [Abstract][Full Text] [Related]
10. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
11. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
Toi M; Saeki T; Aogi K; Sano M; Hatake K; Asaga T; Tokuda Y; Mitsuyama S; Kimura M; Kobayashi T; Tamura M; Tabei T; Shin E; Nishimura R; Ohno S; Takashima S
Jpn J Clin Oncol; 2005 Jun; 35(6):310-5. PubMed ID: 15930037
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
Tominaga T; Abe O; Izuo M; Nomura Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
[TBL] [Abstract][Full Text] [Related]
16. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Pieńkowski T; Jagiello-Gruszfeld A
Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
18. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]